Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia
about
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanismsThe human Cdc37.Hsp90 complex studied by heteronuclear NMR spectroscopyThe C-terminal domain of human Cdc37 studied by solution NMRCdc37 has distinct roles in protein kinase quality control that protect nascent chains from degradation and promote posttranslational maturationERK5 and Cell Proliferation: Nuclear Localization Is What MattersCanonical and kinase activity-independent mechanisms for extracellular signal-regulated kinase 5 (ERK5) nuclear translocation require dissociation of Hsp90 from the ERK5-Cdc37 complexFunctional interaction of human Cdc37 with the androgen receptor but not with the glucocorticoid receptor.Identification and analysis of tumour-associated antigens in hepatocellular carcinoma.The oncoprotein kinase chaperone CDC37 functions as an oncogene in mice and collaborates with both c-myc and cyclin D1 in transformation of multiple tissuesSplit Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) to characterize Hsp90-Cdc37 complex and identify critical residues in protein/protein interactions.Structure of an Hsp90-Cdc37-Cdk4 complex.The proliferation of Drosophila in cancer research: a system for the functional characterization of tumor suppressors and oncogenes.Cdc37 goes beyond Hsp90 and kinasesThe Cdc37 protein kinase-binding domain is sufficient for protein kinase activity and cell viability.Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth.Phosphorylated and unphosphorylated serine 13 of CDC37 stabilize distinct interactions between its client and HSP90 binding domains.Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitorsTargeting the oncogene and kinome chaperone CDC37.The role of stress proteins in prostate cancer.Characterization of celastrol to inhibit hsp90 and cdc37 interaction.Molecular cochaperones: tumor growth and cancer treatment.Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteinsThe novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15.Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts.Mechanisms of Resistance to Hsp90 Inhibitor Drugs: A Complex Mosaic Emerges.Cdc37 is essential for chromosome segregation and cytokinesis in higher eukaryotes.Identification of Cdc37 as a novel regulator of the stress-responsive mitogen-activated protein kinaseInteraction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII.CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone, Cdc37.Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth.Structural bioinformatics and protein docking analysis of the molecular chaperone-kinase interactions: towards allosteric inhibition of protein kinases by targeting the hsp90-cdc37 chaperone machinery.A positive feedback loop between protein kinase CKII and Cdc37 promotes the activity of multiple protein kinases.Cdc37 facilitates cell survival of colorectal carcinoma via activating the CDK4 signaling pathway.Bipartite Role of Heat Shock Protein 90 (Hsp90) Keeps CRAF Kinase Poised for Activation.Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery.
P2860
Q24339394-3F8DB6C4-7880-405B-9FE8-50317FF99FF1Q27653114-1918921E-CC68-4D07-B9DE-DBD391EF95D4Q27702200-53A9EBE3-4E16-4158-89B8-C01DA38E8F96Q27938495-C1E123EB-2DA4-41CC-9D50-1D15E14ADF1FQ28078572-F87D05E4-15A4-4966-B6A3-1AAE12B1519FQ28854310-D7AEF2DB-65BE-4222-B4CF-8DC71AFD6832Q31583023-1BFB7F34-E9F1-4A80-BFC9-9FCAE3128DC7Q33212678-A2B2C492-89A9-4492-A86B-C38D8CE11EA0Q33964019-76FC585B-C8DD-4353-8113-81261DF5586AQ33966866-8592BDF8-A4F2-4930-AE49-F82347F0E310Q34562863-08810A45-DC2E-468D-98FA-2CDD5C5E041DQ34718436-9884DF0B-7810-4D89-99AD-551E75B7C692Q35588824-D18DD8B7-0D2F-4EF2-9046-D944C02F3FFFQ36325580-D3C762B0-C142-453E-9F9B-03549FF1AA82Q36635865-10FDEE80-FABD-48FE-B3CC-A1B1AD46F9F8Q36824214-4A3A0DCA-DEB0-43BF-91F6-7D1C260C5919Q37083059-F949BC9A-5B6D-4D93-BD59-BE9A3EC3FF3DQ37177064-224DB5DC-B96C-49B0-ADCA-43B39FA60A2CQ37223453-BAD03707-D4B9-46D2-81F6-7D6170302066Q37467557-F7F592A5-DD3B-4FB2-BBE3-9F4ED8360FC0Q38166376-A575F841-1F9B-4F25-8F3E-2A64A472784FQ38725015-F193DE06-87CF-4F58-A2A0-CA3AF22E0709Q38793522-D2BB49F4-932A-4823-ADBE-B2FE7D38FC3FQ38913419-7259EB8B-BEF6-4DC3-8E45-BB6CE59C22C8Q38972744-7FAE626C-9556-469D-8952-45989C6E75C2Q38976702-009140F4-7FAB-48EE-BCB3-A275539D374AQ39659016-D233F028-EB3D-4614-AED3-E2E76DADED8FQ39791249-48CF583A-8EEB-40F6-A95A-0EA76809EEAEQ40684830-46ABCD71-9FCA-4ABA-8637-247F58E2F24CQ40763457-E44B023F-B104-4688-B53A-2FC3E45EEA53Q42202989-4B9402AD-A52A-4B12-B22F-73503A0C84A5Q42839646-B7201400-6FBC-4DEF-8B63-2DA60445D5DCQ44219236-EEC718D5-DFE1-45A7-B990-04EA50FD9D8AQ47231838-CD38F3EA-B091-4DFF-B1E0-A049F94B21EAQ51431702-3AE68E33-C198-4226-954A-DDC15893494AQ52716432-35B2EF1C-3A27-4655-AAB9-3581668A5966
P2860
Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia
description
im April 2000 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 April 2000
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2000
@uk
name
Induction of human Cdc37 in pr ...... promote prostatic hyperplasia
@en
Induction of human Cdc37 in pr ...... promote prostatic hyperplasia
@nl
type
label
Induction of human Cdc37 in pr ...... promote prostatic hyperplasia
@en
Induction of human Cdc37 in pr ...... promote prostatic hyperplasia
@nl
prefLabel
Induction of human Cdc37 in pr ...... promote prostatic hyperplasia
@en
Induction of human Cdc37 in pr ...... promote prostatic hyperplasia
@nl
P2093
P2860
P356
P1433
P1476
Induction of human Cdc37 in pr ...... promote prostatic hyperplasia
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.ONC.1203561
P407
P577
2000-04-01T00:00:00Z